JP2024513391A5 - - Google Patents
Info
- Publication number
- JP2024513391A5 JP2024513391A5 JP2023560496A JP2023560496A JP2024513391A5 JP 2024513391 A5 JP2024513391 A5 JP 2024513391A5 JP 2023560496 A JP2023560496 A JP 2023560496A JP 2023560496 A JP2023560496 A JP 2023560496A JP 2024513391 A5 JP2024513391 A5 JP 2024513391A5
- Authority
- JP
- Japan
- Prior art keywords
- lys
- 1peg2
- diacid
- pharmaceutically acceptable
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163169545P | 2021-04-01 | 2021-04-01 | |
| US63/169,545 | 2021-04-01 | ||
| US202263325328P | 2022-03-30 | 2022-03-30 | |
| US63/325,328 | 2022-03-30 | ||
| PCT/US2022/022817 WO2022212700A2 (en) | 2021-04-01 | 2022-03-31 | Conjugated hepcidin mimetics |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024513391A JP2024513391A (ja) | 2024-03-25 |
| JP2024513391A5 true JP2024513391A5 (enExample) | 2025-03-06 |
| JP7849383B2 JP7849383B2 (ja) | 2026-04-21 |
Family
ID=83459967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560496A Active JP7849383B2 (ja) | 2021-04-01 | 2022-03-31 | コンジュゲートされたヘプシジン模倣物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240209053A1 (enExample) |
| EP (1) | EP4314014A4 (enExample) |
| JP (1) | JP7849383B2 (enExample) |
| AU (1) | AU2022249097A1 (enExample) |
| CA (1) | CA3214153A1 (enExample) |
| TW (1) | TW202304952A (enExample) |
| WO (1) | WO2022212700A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| HRP20211448T1 (hr) | 2014-05-16 | 2021-12-24 | Protagonist Therapeutics, Inc. | Alfa4beta7 integrin tioeter peptidni antagonisti |
| CN107206254B (zh) | 2014-07-17 | 2021-08-24 | 领导医疗有限公司 | 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途 |
| CA3089868A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| AU2021209086A1 (en) | 2020-01-15 | 2022-08-04 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| JP7397239B2 (ja) | 2020-11-20 | 2023-12-12 | ヤンセン ファーマシューティカ エヌ．ベー． | インターロイキン－２３受容体のペプチド阻害剤の組成物 |
| EP4370146A4 (en) | 2021-07-14 | 2025-05-21 | Janssen Biotech, Inc. | Lipidated peptide inhibitors of the interleukin-23 receptor |
| EP4472995A4 (en) * | 2022-02-02 | 2025-11-19 | Protagonist Therapeutics Inc | Conjugated hepcidin mimetics |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7192713B1 (en) * | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
| EP1451211A2 (en) * | 2001-03-30 | 2004-09-01 | University of Copenhagen | Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease |
| US9102708B2 (en) | 2006-02-17 | 2015-08-11 | Syngene Limited | Methods for the synthesis of dicarba bridges in organic compounds |
| US8435941B2 (en) * | 2008-12-05 | 2013-05-07 | The Regents Of The University Of California | Mini-hepcidin peptides and methods of using thereof |
| CN107206254B (zh) * | 2014-07-17 | 2021-08-24 | 领导医疗有限公司 | 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途 |
| US20190002503A1 (en) * | 2015-12-30 | 2019-01-03 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| CA3089868A1 (en) * | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
-
2022
- 2022-03-31 CA CA3214153A patent/CA3214153A1/en active Pending
- 2022-03-31 WO PCT/US2022/022817 patent/WO2022212700A2/en not_active Ceased
- 2022-03-31 JP JP2023560496A patent/JP7849383B2/ja active Active
- 2022-03-31 EP EP22782209.5A patent/EP4314014A4/en active Pending
- 2022-03-31 AU AU2022249097A patent/AU2022249097A1/en active Pending
- 2022-03-31 US US18/285,198 patent/US20240209053A1/en active Pending
- 2022-04-01 TW TW111112896A patent/TW202304952A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024513391A5 (enExample) | ||
| JP2023536463A5 (enExample) | ||
| JP2024513392A5 (enExample) | ||
| JP2023540679A5 (enExample) | ||
| US11753443B2 (en) | Conjugated hepcidin mimetics | |
| JP2026012422A (ja) | コンジュゲート型ヘプシジン模倣体 | |
| JP7849383B2 (ja) | コンジュゲートされたヘプシジン模倣物 | |
| JP2009532384A5 (enExample) | ||
| JP2012530145A5 (enExample) | ||
| WO2017117411A1 (en) | Analogues of hepcidin mimetics with improved in vivo half lives | |
| CA3213688A1 (en) | Conjugated hepcidin mimetics | |
| JP2009532385A5 (enExample) | ||
| WO2022212698A1 (en) | Conjugated hepcidin mimetics | |
| JP2024520861A (ja) | 遺伝性ヘモクロマトーシスの治療のためのヘプシジン模倣体 | |
| JP2024520861A5 (enExample) | ||
| US20250170216A1 (en) | Conjugated hepcidin mimetics | |
| KR100360975B1 (ko) | 위장운동자극활성을가지는폴리펩티드 | |
| JP2009519945A5 (enExample) | ||
| RU2006101720A (ru) | Фармацевтическая композиция | |
| JP5279021B2 (ja) | Ｇｐｒ５４アゴニスト活性を有する新規化合物 | |
| AR125266A1 (es) | Miméticos de hepcidina conjugados | |
| IE912378A1 (en) | Derivatives of pituitary posterior lobe hormones | |
| SE501678C2 (sv) | Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid | |
| NZ822560B2 (en) | Novel triple glp-1/gip/glucagon receptor agonist and a pharmaceutical composition for preventing or treating obesity comprising the same | |
| NZ822560A (en) | Novel triple glp-1/gip/glucagon receptor agonist and a pharmaceutical composition for preventing or treating obesity comprising the same |